Thrombosis Clinical Trial
Official title:
Evaluation of the Potential Action of Coagulation Factors Concentrates in the Reversal of the Antithrombotic Action of New Oral Anticoagulants: Studies ex Vivo in Blood Samples From Healthy Volunteers
The main goal of this study is to improve safety and efficiency of clinical practice with the
new generation of oral anticoagulants.
1. To determine the effect of new oral anticoagulants (dabigatran and rivaroxaban) on
platelets and coagulation mechanisms under flow conditions.
2. To evaluate the ability of the concentrates containing coagulation factors (PCCs and
FVIIa) to reverse the effects induced by the new anticoagulants.
These studies will be carried out ex vivo in blood samples obtained from healthy volunteers
undergoing oral anticoagulant therapy at doses of proven efficacy and safety used in previous
clinical trials.
There is a lack of information on antidotes that could reverse the effects of new oral
anticoagulants in patients that require a rapid restoration of their impaired hemostatic
mechanisms. The present study seeks to improve the security and efficacy of the clinical
practice with the new generation of oral anticoagulants.
OBJECTIVES:
1. To assess the action of new oral anticoagulants (dabigatran y rivaroxaban) on hemostasis
with specific interest on possible interference with platelet interactions and
coagulation mechanisms under flow conditions;
2. To evaluate comparatively the effects of coagulation factor concentrates of established
efficacy (prothrombin complexes and rFVIIa) to reverse the alterations of hemostasis
parameters induced by the new anticoagulants.
METHODOLOGY:
Studies will be performed ex vivo using blood samples from healthy individuals subjected to
treatments with the new anticoagulants at doses of proven efficacy and safety (150mg/12 h for
dabigatran and 20 mg/day for rivaroxaban). Blood samples from the participants will be spiked
"in vitro" with know concentrations of the coagulation factors. Modifications in:
- morphometric parameters (platelet deposition and fibrin formation) in perfusion studies
under flow conditions; and
- analytical tests evaluating changes in coagulation mechanisms (thrombin generation,
ecarine and prothrombin times) will be determined.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT05426564 -
Exploratory Assessment of the Quantra® System in Adult ECMO Patients
|
||
Not yet recruiting |
NCT05830916 -
Diagnostic Role of Antiphospholipid Antibodies and Microparticles in Immune Thrombocytopenic Patients With Thrombosis
|
||
Recruiting |
NCT02972385 -
Pharmacogenomics of Warfarin in Hispanics and Latinos
|
||
Completed |
NCT02917213 -
Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
|
||
Completed |
NCT02526628 -
Thrombosis and Neurocognition in Klinefelter Syndrome
|
||
Completed |
NCT02439190 -
CV004-007 Thrombosis Chamber Study
|
Phase 1 | |
Completed |
NCT02341638 -
Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01855516 -
Partial Thromboplastin Time After 72 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin
|
N/A | |
Unknown status |
NCT00983112 -
Evicel Study on the Peri-operative Bleeding in Total Knee Prothesis Surgery
|
Phase 4 | |
Completed |
NCT00412464 -
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
|
Phase 1 | |
Completed |
NCT00346424 -
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters
|
Phase 3 | |
Completed |
NCT00479362 -
Anticoagulant Therapy During Pacemaker Implantation
|
Phase 4 | |
Completed |
NCT00143715 -
Oral Vitamin K for Warfarin Associated Coagulopathy
|
Phase 3 | |
Terminated |
NCT00303420 -
Alteplase for Blood Flow Restoration in Hemodialysis Catheters
|
Phase 4 | |
Completed |
NCT00039858 -
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
|
Phase 4 | |
Completed |
NCT00007410 -
Genetic Architecture of Plasma T-PA and PAI-1
|
N/A | |
Completed |
NCT00000538 -
Dietary Effects on Lipoproteins and Thrombogenic Activity
|
Phase 3 | |
Completed |
NCT00005436 -
Lupus Cohort--Thrombotic Events and Coronary Artery Disease
|
N/A |